Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer?
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/nrclinonc.2017.125
Abstract: Potential strategies for improving the outcomes of patients with early stage HER2-positive (HER2+) breast cancer have included dual anti-HER2 therapy. Recent results from the APHINITY trial show a statistically significant, but clinically modest, benefit from… read more here.
Keywords: lies beyond; her2 positive; cancer lies; breast cancer ... See more keywords